Modulation of Alendronate release from a calcium phosphate bone cement: An in vitro osteoblast-osteoclast co-culture study.


Journal

International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127

Informations de publication

Date de publication:
10 Jan 2019
Historique:
received: 25 08 2018
revised: 07 11 2018
accepted: 09 11 2018
pubmed: 14 11 2018
medline: 4 4 2019
entrez: 14 11 2018
Statut: ppublish

Résumé

In this study, we loaded a biomimetic calcium phosphate bone cement (CPC) with relatively high amounts of a bisphosphonate through the use of Solid Lipid Microparticles (MPs) and investigated bone cells response to the composite cements. 10, 20 and 30% w/w of Alendronate (AL) were successfully introduced into microparticles of Cutina HR and Precirol, which were prepared by means of spray-congealing technique. Addition of AL-loaded MPs to the cement composition provoked a lengthening of the setting and of the hardening processes. However, setting times were still in a range useful for clinical applications, except for the cements at the highest Alendronate content. The composite cements displayed a sustained drug release over time. Cements with the best performances in terms of setting, hardening, mechanical properties and drug release were submitted to in vitro tests using a co-culture model of osteoblast and osteoclast. The results showed that the use of MPs to enrich the cement composition with Alendronate provides materials able to inhibit osteoclast viability and activity, while promoting osteoblast viability and earlier differentiation, indicating that the MPs-cements are good delivery systems for bisphosphonates.

Identifiants

pubmed: 30423416
pii: S0378-5173(18)30841-X
doi: 10.1016/j.ijpharm.2018.11.023
pii:
doi:

Substances chimiques

Bone Cements 0
Bone Density Conservation Agents 0
Calcium Phosphates 0
Delayed-Action Preparations 0
Lipids 0
calcium phosphate 97Z1WI3NDX
Alendronate X1J18R4W8P

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

245-255

Informations de copyright

Copyright © 2018 Elsevier B.V. All rights reserved.

Auteurs

Luisa Stella Dolci (LS)

Department of Pharmacy and BioTechnology, University of Bologna, Via S. Donato 19/2, 40127, Italy.

Silvia Panzavolta (S)

Department of Chemistry "G. Ciamician", University of Bologna, Via Selmi 2, 40126, Italy. Electronic address: silvia.panzavolta@unibo.it.

Paola Torricelli (P)

Laboratory of Preclinical and Surgery Studies, IRCCS Rizzoli Orthopaedic Institute, via di Barbiano 1-10, 40136 Bologna, Italy.

Beatrice Albertini (B)

Department of Pharmacy and BioTechnology, University of Bologna, Via S. Donato 19/2, 40127, Italy.

Laura Sicuro (L)

Laboratory of Preclinical and Surgery Studies, IRCCS Rizzoli Orthopaedic Institute, via di Barbiano 1-10, 40136 Bologna, Italy.

Milena Fini (M)

Laboratory of Preclinical and Surgery Studies, IRCCS Rizzoli Orthopaedic Institute, via di Barbiano 1-10, 40136 Bologna, Italy.

Adriana Bigi (A)

Department of Chemistry "G. Ciamician", University of Bologna, Via Selmi 2, 40126, Italy.

Nadia Passerini (N)

Department of Pharmacy and BioTechnology, University of Bologna, Via S. Donato 19/2, 40127, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH